Compare TSLX & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TSLX | EVO |
|---|---|---|
| Founded | 2010 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 934.1M |
| IPO Year | 2011 | N/A |
| Metric | TSLX | EVO |
|---|---|---|
| Price | $17.71 | $2.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 1 |
| Target Price | ★ $21.61 | $7.00 |
| AVG Volume (30 Days) | ★ 763.2K | 94.1K |
| Earning Date | 05-05-2026 | 04-08-2026 |
| Dividend Yield | ★ 10.82% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.37 |
| Revenue Next Year | $1.20 | $10.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.99 | $2.31 |
| 52 Week High | $25.17 | $4.80 |
| Indicator | TSLX | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 41.95 | 36.25 |
| Support Level | $17.25 | $2.32 |
| Resistance Level | $18.65 | $3.78 |
| Average True Range (ATR) | 0.50 | 0.09 |
| MACD | -0.16 | -0.06 |
| Stochastic Oscillator | 16.86 | 6.44 |
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. The company partners with other companies across a variety of industries and provides creative solutions with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.